LifeMD Inc
$ 3.77
-3.58%
14 Apr - close price
- Market Cap 187,578,000 USD
- Current Price $ 3.77
- High / Low $ 4.25 / 3.74
- Stock P/E N/A
- Book Value 0.50
- EPS -0.30
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -1.31 %
- 52 Week High 15.84
- 52 Week Low 2.56
About
LifeMD, Inc. is a direct-to-patient telehealth company connecting consumers with healthcare professionals for care in various indications, including concierge care, men's sexual health, dermatology, and others in the United States. . The company is headquartered in New York, New York.
Analyst Target Price
$9.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-17 | 2025-08-05 | 2025-05-06 | 2025-03-10 | 2024-11-07 | 2024-08-07 | 2024-05-08 | 2024-03-11 | 2023-11-08 | 2023-08-09 | 2023-05-12 |
| Reported EPS | 0.0568 | -0.1 | -0.06 | 0.0282 | 0.21 | -0.14 | -0.19 | -0.19 | -0.12 | -0.2 | -0.23 | -0.15 |
| Estimated EPS | -0.065 | -0.04 | -0.02 | 0.14 | 0.14 | -0.12 | -0.12 | -0.15 | -0.14 | -0.15 | -0.1 | -0.16 |
| Surprise | 0.1218 | -0.06 | -0.04 | -0.1118 | 0.07 | -0.02 | -0.07 | -0.04 | 0.02 | -0.05 | -0.13 | 0.01 |
| Surprise Percentage | 187.3846% | -150% | -200% | -79.8571% | 50% | -16.6667% | -58.3333% | -26.6667% | 14.2857% | -33.3333% | -130% | 6.25% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LFMD
2026-04-10 16:38:54
LifeMD, Inc. (NASDAQ:LFMD) has announced the addition of Eli Lilly’s oral weight loss drug, Foundayo (orforglipron), to its weight management program. This FDA-approved, once-daily oral treatment is available to eligible LifeMD patients, with pricing options including a self-pay price of $149 per month for the initial dosage and potential savings for those with commercial insurance. The move bolsters LifeMD's offerings in the growing GLP-1 therapy market and coincides with strong operational momentum, including 25% revenue growth over the last year, and positive analyst forecasts predicting profitability.
2026-04-05 17:09:54
This article provides a technical analysis of LifeMD Inc (LFMD), indicating a current Neutral consensus based on various indicators. While some moving averages and oscillators suggest buy signals, the stock is trading below its 200-day moving average, a key indicator for long-term trends. Key support and resistance levels are identified for traders.
2026-03-24 05:39:40
LifeMD, Inc. (Nasdaq: LFMD) has announced a cash dividend for its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP), totaling $0.5546875 per share. This dividend will be paid on April 15, 2026, to shareholders of record as of April 3, 2026. LifeMD specializes in virtual primary care services, including telemedicine, lab services, and specialized treatments across a wide range of conditions.
2026-03-11 11:52:38
HC Wainwright has increased its price target for LifeMD (NASDAQ:LFMD) from $9.00 to $10.00, maintaining a "buy" rating and suggesting a significant upside. Despite this, analyst opinions are varied, with a "Moderate Buy" consensus and an average target of $8.57, as several other firms have recently lowered their targets or ratings. The company recently missed earnings estimates for its last quarter, with EPS of -$0.04 against an expected -$0.01, and revenues of $46.87 million against analyst estimates of $48.57 million.
2026-02-20 16:25:19
Nine research firms have given LifeMD, Inc. (NASDAQ:LFMD) an average recommendation of "Moderate Buy," with an average 12-month price target of $9.25, suggesting significant upside from its current price of approximately $2.90. However, recent analyst actions indicate weakening sentiment, with several firms lowering price targets and one downgrading the stock to "sell." The company recently missed quarterly earnings and revenue estimates, and notable insider selling has occurred.
2026-02-20 02:36:00
This article analyzes Lifemd Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ: LFMDP) using AI models. It identifies a strong near-term sentiment but a neutral mid and long-term outlook, highlighting an exceptional 12.0:1 risk-reward setup. The analysis provides specific trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
